CFDB - Cystic Fibrosis DataBase

  1. Home
  2. Database
Search (?)
at least one term
all terms
Advanced search
primary studies published RCT

Moderate intensity exercise mediates comparable increases in exhaled chloride as albuterol in individuals with cystic fibrosis.

  • Year: 2015
  • Date: 2019
  • Author: Wheatley CM
Source

Respir Med. 2015 Aug;109(8):1001-11. doi: 10.1016/j.rmed.2015.05.018. Epub 2015 May 23.

Study design (if review, criteria of inclusion for studies)

Double-blind randomized crossover trial.

Participants

Six participants with CF and IGT were studied on 2 days.

Interventions

After overnight fasting, patients received exenatide 2.5 mcg or placebo (0.9% saline) subcutaneously 15 minutes before a pancake meal labelled with (13) C octanoate and pancreatic enzyme replacement.

Outcome measures

Primary outcomes: area under the curve over 240 minutes (AUC 240 ) for blood glucose and peak blood glucose. Secondary outcomes: AUC240 for insulin, C-peptide, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)

Main results

The primary outcomes, area under the curve over 240 minutes (AUC 240 ) for blood glucose (P < 0.0001) and peak blood glucose (7.65 mM +/- 0.34 [mean +/- SE] vs 9.53 mM +/- 0.63, P < 0.0001), were markedly lower after exenatide than placebo. AUC240 for insulin, C-peptide, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) was also lower after exenatide. Gastric emptying was markedly slower after exenatide, as assessed by time for 10% gastric emptying and peak (13) CO2 excretion.

Authors' conclusions

Exenatide corrects postprandial hyperglycaemia in young people with CF and IGT. GLP-1 agonists are a candidate treatment in CF-related diabetes.

Keywords: Adult; Child; Diabetes Mellitus; Gastrointestinal Diseases; Glucose Intolerance; Hypoglycemic Agents; Pancreatic Diseases; pharmacological_intervention; GLP-1 agonists; exenatide;